ArticleGates open research2020
Value-based tiered pricing for universal health coverage: an idea worth revisiting.
Article in Gates open research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Analysis of insecticide-treated bednet market dynamics between 2004-2021 and monetary value of additional bednet longevity.Cost effectiveness and resource allocation : C/E · 2026Article
- Strategic purchasing of oncology drugs to improve affordability and access to cancer care in India.The Lancet regional health. Southeast Asia · 2026Review
- Immunotherapy in Asia: current insights and prospects in Southeast Asia and Malaysia.Frontiers in oncology · 2026Review
- Collective international action to increase access to costly drugs: pooled procurement and equity based tiered pricing.BMJ (Clinical research ed.) · 2025Article
- Unlocking patient access to gene therapy: five key practices.Gene therapy · 2025Article
- Clinical trials to gene therapy development and production in Brazil: a review.Lancet regional health. Americas · 2025Review
- Development of a value assessment framework for Health Technology Assessment in rare diseases drugs: insights from a Delphi study in Brazil.International journal of technology assessment in health care · 2025Article
- Drivers of innovation value: simulation for new drug pricing evaluation based on system dynamics modelling.Frontiers in pharmacology · 2025Article
- Market Transparency in Medicine Pricing: Pathways to Fair Pricing.PharmacoEconomics · 2024Article
- Prices of paediatric vaccines in European vaccination programmes.Vaccine: X · 2023Article
- Antihypertensive medicine use differs between Ghana and Nigeria.BMC cardiovascular disorders · 2022Article
- Public support in the United States for global equity in vaccine pricing.Scientific reports · 2022Article
- Public health policies for the common interest: rethinking EU states' incentives strategies when a pandemic reshuffles all interests.The European journal of health economics : HEPAC : health economics in prevention and care · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The pricing of medicines and health products ranks among the most hotly debated topics in health policy, generating controversy in richer and poorer markets alike. Creating the right pricing structure for pharmaceuticals and other healthcare products is particularly important for low- and middle-income countries, where pharmaceuticals account for a significant portion of total health expenditure; high medicine prices therefore threaten the feasibility and sustainability of nascent schemes for universal health coverage (UHC). We argue that a strategic system of value-based tiered pricing (VBTP), wherein each country would pay a price for each health product commensurate with the local value it provides, could improve access, enhance efficiency, and empower countries to negotiate with product manufacturers. This paper attempts to further understanding on the potential value of tiered pricing, barriers to its implementation, and potential strategies to overcome those.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.